Teleflex (NYSE:TFX) Rating Increased to Hold at UBS Group

Teleflex (NYSE:TFX) was upgraded by stock analysts at UBS Group to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other research analysts have also weighed in on the company. Mizuho lifted their price objective on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $140.00 to $160.00 in a report on Monday, June 8th. Raymond James Financial restated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a report on Friday, May 8th. Wells Fargo & Company raised their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Zacks Research upgraded shares of Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $147.70.

Teleflex Stock Up 2.4%

Shares of NYSE TFX opened at $134.16 on Tuesday. The company has a market capitalization of $5.94 billion, a P/E ratio of -5.88, a price-to-earnings-growth ratio of 0.97 and a beta of 0.82. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The company’s 50 day moving average price is $130.88 and its 200-day moving average price is $120.95.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. During the same period in the prior year, the company posted $1.44 earnings per share. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities analysts forecast that Teleflex will post 6.7 earnings per share for the current year.

Institutional Trading of Teleflex

Several hedge funds have recently bought and sold shares of the business. Empowered Funds LLC increased its stake in Teleflex by 15.8% during the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Teleflex by 42.6% during the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after buying an additional 1,895 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Teleflex by 32.7% during the second quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock valued at $1,614,000 after buying an additional 3,360 shares during the last quarter. Invesco Ltd. increased its position in shares of Teleflex by 1.2% during the second quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company’s stock worth $16,040,000 after acquiring an additional 1,659 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after acquiring an additional 521 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.